<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biomea Fusion Inc — News on 6ix</title>
<link>https://6ix.com/company/biomea-fusion-inc</link>
<description>Latest news and press releases for Biomea Fusion Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 21:37:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biomea-fusion-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354e4a78dffbe2df0e64cd.webp</url>
<title>Biomea Fusion Inc</title>
<link>https://6ix.com/company/biomea-fusion-inc</link>
</image>
<item>
<title>Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment</guid>
<pubDate>Mon, 27 Apr 2026 21:37:00 GMT</pubDate>
<description>A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and dem</description>
</item>
<item>
<title>Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1</description>
</item>
<item>
<title>Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-reports-full-year-2025-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-reports-full-year-2025-financial-results-and-corporate-highlights</guid>
<pubDate>Tue, 24 Mar 2026 20:05:00 GMT</pubDate>
<description>Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026Initiated Phase I trial enrollment of GLP-131 (BMF-650 in obesity) with initial 28-day weight reduction data expected in the second quarter of 2026Projected cash runway into the first quarter</description>
</item>
<item>
<title>Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-presents-phase-ii-covalent-111-data-in-type-2-diabetes-at-the-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes-2026</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-presents-phase-ii-covalent-111-data-in-type-2-diabetes-at-the-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes-2026</guid>
<pubDate>Sat, 14 Mar 2026 08:30:00 GMT</pubDate>
<description>SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company’s Phase II COVALENT-111 study evaluating the effi</description>
</item>
<item>
<title>Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-enters-2026-focused-130000508</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-enters-2026-focused-130000508</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond t</description>
</item>
<item>
<title>Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-present-44th-annual-120000144</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-present-44th-annual-120000144</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from</description>
</item>
<item>
<title>Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-kol-presentation-233500551</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-kol-presentation-233500551</guid>
<pubDate>Tue, 09 Dec 2025 23:35:00 GMT</pubDate>
<description>Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Profess</description>
</item>
<item>
<title>Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-presents-covalent-111-120000873</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-presents-covalent-111-120000873</guid>
<pubDate>Fri, 05 Dec 2025 12:00:00 GMT</pubDate>
<description>Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 DiabetesSAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib,</description>
</item>
<item>
<title>Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-oral-presentation-211000155</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-oral-presentation-211000155</guid>
<pubDate>Mon, 01 Dec 2025 21:10:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments f</description>
</item>
<item>
<title>Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-inc-reports-inducement-210500648</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-inc-reports-inducement-210500648</guid>
<pubDate>Mon, 01 Dec 2025 21:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to</description>
</item>
<item>
<title>Biomea Fusion to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-upcoming-investor-120000147</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-upcoming-investor-120000147</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference: Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings on December 2, 2025 in New York, NY.8th Annual Evercore Healthcare Conference: Biomea will participat</description>
</item>
<item>
<title>Biomea Fusion to Participate at Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-jefferies-london-120000618</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-jefferies-london-120000618</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 17, 2025 at 4:30 PM (GMT) and will participate in one-on-one meetings on November 17-18, 2025 in London, UK. An audio webcast of the presentation will be available here or by vis</description>
</item>
<item>
<title>Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-showcases-preclinical-advances-120000648</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-showcases-preclinical-advances-120000648</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of BMF-650 in healthy obese patients is currently enrolling with data expected first half of 2026In a rodent model of type 2 diabetes (“T2D”), icovamenib in combination with low dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, o</description>
</item>
<item>
<title>Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-reports-third-quarter-210500140</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-reports-third-quarter-210500140</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), dosing its first patient in a Phase I clinical trialPresented preclinical activity of icovamenib in combination with semaglutide in type 2 diabetes (“T2D”) animal model at EASD Annual Meeting, demonstrating enhanced glycemic control and body weight reduction with preservation o</description>
</item>
<item>
<title>Biomea Fusion to Present Poster Presentations at ObesityWeek®2025</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-present-poster-presentations-120000600</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-present-poster-presentations-120000600</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia. The presentations will highlight preclinical data for BMF-650, Biomea’s next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), and combination data for icovamenib, the c</description>
</item>
<item>
<title>Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-first-patient-120000488</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-first-patient-120000488</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in a Phase I clinical trial of BMF-650, the Company’s investigational, next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”). BMF-650 is an orally administere</description>
</item>
<item>
<title>Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-citis-smid-230500844</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-participate-citis-smid-230500844</guid>
<pubDate>Tue, 21 Oct 2025 23:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. A live audio webcast of the discussion will be available here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-event</description>
</item>
<item>
<title>Biomea Fusion Announces Pricing of Public Offering of Securities</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-pricing-public-120000927</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-pricing-public-120000927</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 11,195,121 shares of its common stock and accompanying warrants to purchase an aggregate of 11,195,121 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to pur</description>
</item>
<item>
<title>Biomea Fusion Announces Proposed Public Offering of Securities</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-proposed-public-201800638</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-proposed-public-201800638</guid>
<pubDate>Mon, 06 Oct 2025 20:18:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchas</description>
</item>
<item>
<title>Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations</title>
<link>https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-positive-52-200300726</link>
<guid isPermaLink="true">https://6ix.com/company/biomea-fusion-inc/news/biomea-fusion-announces-positive-52-200300726</guid>
<pubDate>Mon, 06 Oct 2025 20:03:00 GMT</pubDate>
<description>Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo adjusted mean reduction in HbA1c (Arm B)Type 2 diabetes patients on a GLP-1-based therapy failing to achieve their target HbA1c also showed a clinically meaningful response from only 12 weeks of icovamenib treatment with a mean placebo adjusted HbA1c reduction o</description>
</item>
</channel>
</rss>